{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:06:55Z","timestamp":1789056415286,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023296","name":"Alliance Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201808","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:44:01Z","timestamp":1783640641000},"page":"201808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1328-5964","authenticated-orcid":false,"given":"Alessia","family":"Ugolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bercher-Brayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Cesarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Camisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Carulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-366X","authenticated-orcid":false,"given":"Giuseppe Alvise","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rudilosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-315X","authenticated-orcid":false,"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cesana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-2139","authenticated-orcid":false,"given":"Matteo","family":"Doglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201808_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De Paula Pohl","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.omta.2026.201808_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102476","article-title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","volume":"69","author":"Greco","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.omta.2026.201808_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201808_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/0886022X.2018.1456462","article-title":"Low-dose IL-2 expands CD4+ regulatory T cells with a suppressive function in vitro via the STAT5-dependent pathway in patients with chronic kidney diseases","volume":"40","author":"Li","year":"2018","journal-title":"Ren. Fail."},{"key":"10.1016\/j.omta.2026.201808_bib6","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136185","article-title":"CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD","volume":"5","author":"Imura","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.omta.2026.201808_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2019.00159","article-title":"The Regulatory T Cell in Active Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-Analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib8","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201808_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cei.13297","article-title":"Methods to manufacture regulatory T cells for cell therapy","volume":"197","author":"MacDonald","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib12","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2019001248","article-title":"IL-2 enhances ex vivo\u2013expanded regulatory T-cell persistence after adoptive transfer","volume":"4","author":"Furlan","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201808_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201808_bib14","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201808_bib15","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201808_bib16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201808_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/eji.200838904","article-title":"Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation","volume":"39","author":"Hoffmann","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219086120","article-title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","volume":"120","author":"Lamarche","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omta.2026.201808_bib19","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.4049\/jimmunol.179.8.5109","article-title":"Expression of CD80\/86 on B Cells Is Essential for Autoreactive T Cell Activation and the Development of Arthritis","volume":"179","author":"O\u2019Neill","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1513009","article-title":"CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs","volume":"16","author":"Doglio","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s41409-025-02553-x","article-title":"Regulatory T cell therapy for Graft-versus-Host Disease","volume":"60","author":"Lysandrou","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omta.2026.201808_bib22","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.21037\/atm-21-3812","article-title":"Study on the preparation and function of regulatory T cells from human peripheral blood","volume":"9","author":"Zuo","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.omta.2026.201808_bib23","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.exphem.2011.08.010","article-title":"Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity","volume":"39","author":"Ukena","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omta.2026.201808_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","article-title":"FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII","volume":"129","author":"Yoon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201808_bib25","doi-asserted-by":"crossref","first-page":"104224","DOI":"10.1016\/j.cellimm.2020.104224","article-title":"Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor","volume":"358","author":"Radichev","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omta.2026.201808_bib27","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/cti.2015.43","article-title":"Treg activation defect in type 1 diabetes: correction with TNFR2 agonism","volume":"5","author":"Okubo","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.omta.2026.201808_bib28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of Immune-Modulatory Drugs on Regulatory T Cell","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.omta.2026.201808_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood.V114.22.666.666","article-title":"Rapamycin-Based GvHD Prophylaxis Is Effective in T-Cell Replete Unmanipulated Haploidentical Peripheral Stem Cell Transplantation for Advanced Haematological Malignancies: Results in 46 Patients","volume":"114","author":"Peccatori","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201808_bib30","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/s41467-021-26844-1","article-title":"Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction","volume":"12","author":"Lamarth\u00e9e","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201808_bib31","doi-asserted-by":"crossref","first-page":"eadj9331","DOI":"10.1126\/scitranslmed.adj9331","article-title":"Human OX40L\u2013CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity","volume":"16","author":"Rui","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201808_bib32","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ymthe.2017.10.019","article-title":"CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape","volume":"26","author":"Pettitt","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201808_bib33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.mt.6300341","article-title":"Generation of Potent and Stable Human CD4+ T Regulatory Cells by Activation-independent Expression of FOXP3","volume":"16","author":"Allan","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201808_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s42003-024-07381-1","article-title":"Metabolic reprogramming of na\u00efve regulatory T cells by IL-7 and IL-15 promotes their persistence and performance upon adoptive transfer","volume":"8","author":"Filoni","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omta.2026.201808_bib35","doi-asserted-by":"crossref","first-page":"12163","DOI":"10.18632\/oncotarget.7512","article-title":"Human na\u00efve regulatory T-cells feature high steady-state turnover and are maintained by IL-7","volume":"7","author":"Silva","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omta.2026.201808_bib36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.omta.2026.201808_bib37","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.omta.2026.201808_bib39","first-page":"9","article-title":"Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene","author":"Casucci","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.omta.2026.201808_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity","volume":"3","author":"Hudecek","year":"2015","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.omta.2026.201808_bib38","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41591-021-01389-4","article-title":"Retrieval of vector integration sites from cell-free DNA","volume":"27","author":"Cesana","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201808_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12859-017-1937-9","article-title":"VISPA2: a scalable pipeline for high-throughput identification and annotation of vector integration sites","volume":"18","author":"Spinozzi","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.omta.2026.201808_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac551","article-title":"ISAnalytics enables longitudinal and high-throughput clonal tracking studies in hematopoietic stem cell gene therapy applications","volume":"24","author":"Pais","year":"2023","journal-title":"Briefings in Bioinformatics"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:02Z","timestamp":1789053242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001436"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201808","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient-derived CAR-Tregs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201808"}}